Persistence with Statins and Incident Cataract: A Population-Based Historical Cohort Study

Annals of Epidemiology

Volumn 20, Issue 2, 2010, Pages 136-142

  Chodick, Gabriel ^a   Heymann, Anthony D ^a   Flash, Shira ^a   Kokia, Ehud ^a   Shalev, Varda ^a  

^a MACCABI HEALTHCARE SERVICES   (Israel)

Author keywords

Cataract; Israel; Lens Opacities; Statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGE; AGED; ARTICLE; CATARACT; CATARACT EXTRACTION; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG USE; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; ISRAEL; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; OUTCOME ASSESSMENT; POPULATION RESEARCH; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SEX DIFFERENCE;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; CATARACT; CATARACT EXTRACTION; COHORT STUDIES; FEMALE; HEALTH MAINTENANCE ORGANIZATIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ISRAEL; MALE; MEDICAL RECORDS; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 73249147692     PISSN: 10472797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.annepidem.2009.10.007     Document Type: Article

References (32)

1. Congdon N., Vingerling J.R., Klein B.E., West S., Friedman D.S., Kempen J., et al. Prevalence of cataract and pseudophakia/aphakia among adults in the United States. Arch Ophthalmol 122 (2004) 487-494
2. Avisar R., Friling R., Snir M., Avisar I., and Weinberger D. Estimation of prevalence and incidence rates and causes of blindness in Israel, 1998-2003. Isr Med Assoc J 8 (2006) 880-881
3. Ellwein L.B., and Urato C.J. Use of eye care and associated charges among the Medicare population: 1991-1998. Arch Ophthalmol 120 (2002) 804-811
4. Strandberg T., Pyörälä K., Cook T., Wilhelmsen L., Faergeman O., Thorgeirsson G., et al. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 364 (2004) 771-777
5. Sacks F., Pfeffer M., Moye L., Rouleau J., Rutherford J., Cole T., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335 (1996) 1001-1009
6. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels. N Engl J Med 339 (1998) 1349-1357
7. Schwartz G., Olsson A., and Ezekowitz M.D. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285 (2001) 1711-1718
8. Watanabe T., Yasunari K., and Nakamura M. Antioxidative actions of statins: potential mechanisms for antiathersclerotic effects. Mini Rev Med Chem 6 (2006) 505-508
9. Smeeth L., Hubbard R., and Fletcher A. Cataract and the use of statins: a case-control study. Q J Med 96 (2003) 337-343
10. Schlienger R., Haefeli W., Jick H., and Meier C. Risk of cataract in patients treated with statins. Arch Intern Med 161 (2001) 2021-2026
11. Klein B., Klein R., Lee K., and Grady L. Statin use and incident nuclear cataract. JAMA 295 (2006) 2752-2758
12. Tan J., Mitchell P., Rochtchina E., and Wang J. Statin use and the long-term risk of incident cataract: the Blue Mountains Eye Study. Am J Ophthalmol 143 (2007) 687-689
13. Chodick G., Shalev V., Gerber Y., Heymann A.D., Silber H., Simah V., et al. Long-term persistence with statin treatment in a not-for-profit health maintenance organization: a population-based retrospective cohort study in Israel. Clin Ther 30 (2008) 2167-2179
14. Shalev V., Chodick G., Silber H., Kokia E., Jan J., and Heymann A.D. Continuation of statin treatment and all-cause mortality: a population-based cohort study. Arch Intern Med 169 (2009) 260-268
15. Kopjar B., Sales A., Pineros S., Sun H., Li Y., and Hedeen A. Adherence with statin therapy in secondary prevention of coronary heart disease in veterans administration male population. Am J Cardiol 92 (2003) 1106-1108
16. Avorn J., Monette J., Lacour A., Bohn R., Monane M., Mogun H., et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA 279 (1998) 1458-1462
17. Benner J., Tierce J., Ballantyne C., Prasad C., Bullano M., Willey V., et al. Follow-up lipid tests and physician visits are associated with improved adherence to statin therapy. Pharmacoeconomics 22 Suppl. 3 (2004) 13-23
18. Israel Central Bureau of Statistics. 1995 Census of Population and Housing Jerusalem; 1998.
19. Chodick G., Heymann A.D., Shalev V., and Kookia E. The epidemiology of diabetes in a large Israeli HMO. Eur J Epidemiol 18 (2003) 1143-1146
20. Valuck R., Williams S., MacArthur M., Saseen J., Nair K., McCollum M., et al. A retrospective cohort study of correlates of response to pharmacologic therapy for hyperlipidemia in members of a managed care organization. Clin Ther 25 (2003) 2936-2957
21. Meyer J., Schultz J., O'Donnell J., Patel P., and Sasane R. Patterns and effectiveness of lipid-lowering therapies in a managed care environment Value Health 8 (2005) 601-612
22. Jones P., Kafonek S., Laurora I., and Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 81 (1998) 582-587
23. Dujovne C., Knopp R., Kwiterovich P., Hunninghake D., McBride T., and Poland M. Randomized comparison of the efficacy and safety of cerivastatin and pravastatin in 1030 hypercholesterolemic patients; the Cerivastatin Study Group. May Clin Proc 75 (2000) 1124-1132
24. Cox D.R. Regression models and life tables (with discussion). J R Stat Soc B 32 (1972) 187-220
25. Schmidt J., Schmitt C., and Hockwin O. No lens changes caused by simvastatin: results from a prospective drug safety study. Lens Eye Toxic Res 7 (1990) 643-650
26. Behrens-Baumann W., Thiery J., Fieseler H., and Seidel D. Pravastatin-ocular side effects after a two year follow-up?. Lens Eye Toxic Res 7 (1990) 311-318
27. Harris M., Bron A., Brown N., Keech A., Wallendszus K., Armitage J., et al. Absence of effect of simvastatin on the progression of lens opacities in a randomised placebo controlled study. Br J Ophthalmol 79 (1995) 996-1002
28. Gerson R., MacDonald J., Alberts A., Chen J., Yudkovich J.B., Greenspan M.D., et al. On the etiology of subcapsular lenticular opacities produced in dogs receiving HMG-CoA reductase inhibitors. Exp Eye Res 50 (1990) 65-78
29. Mukesh B.N., Le A., Dimitrov P.N., Ahmed S., Taylor H.R., and McCarty C.A. Development of cataract and associated risk factors: the Visual Impairment Project. Arch Ophthalmology 124 (2006) 79-85
30. Benner J.S., Glynn R.J., Mogun H., Neumann P.J., Weinstein M.C., and Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA 288 (2002) 455-461
31. Ruigomez A., Garcia Rodriguez L., Dev V., Arellano F., and Raniwala J. Are schizophrenia or antipsychotic drugs a risk factor for cataracts?. Epidemiology 11 (2000) 620-623
32. West S., and Valmadrid C. Epidemiology of risk factors for age-related cataract. Surv Ophthalmol 39 (1995) 323-334